LILA Sciences
AI and automation co-evolving to solve the hardest problems in medicine
About LILA Sciences
Funding & Growth
✓ Pros
- • Highest ML/AI compensation in the biopharma space — salary ceiling $570K as of Q2 2026
- • Frontier AI research applied directly to autonomous drug discovery
- • Flagship Pioneering backing with long-horizon mission
- • Rare combination of robotics, lab automation, and foundation model research
- • Cambridge MA and San Francisco — dual hub presence
- • Active hiring across all seniority levels including staff and principal
✗ Cons
- • Private startup — compensation is equity-heavy with inherent valuation risk
- • Physical Sciences focus (materials, chemistry) is not relevant to most bio candidates
- • Very broad mandate ('scientific superintelligence') means roles can be ambiguous
- • Early-stage company dynamics — processes and teams still being built
- • Most high-comp ML roles are SF-based, not Cambridge
🏢 Working Here
LILA Sciences is a Flagship Pioneering company building an AI + lab automation platform it calls 'autonomous scientific discovery.' Unlike biotech companies that use AI as a tool within a traditional drug discovery pipeline, LILA is building the platform itself — where AI models and robotic labs co-evolve to run experiments, interpret results, and generate new hypotheses without human bottlenecks at each step.
The Life Sciences AI (LSAI) division focuses on foundation models for biology: generative models for protein design, multi-modal reasoning over scientific literature and experimental data, and AI for cell biology spanning single-cell omics and microscopy.
A separate Physical Sciences division works on materials, chemistry, and condensed matter — largely separate from the biology track.
Headquartered in Cambridge, MA with a growing SF office for the LSAI team, LILA is one of the few companies in biopharma that competes directly with tech companies for ML talent — and pays accordingly.
🧬 Bioinformatics Focus
Lila's computational biology work sits within the Life Sciences AI (LSAI) organization and spans several distinct teams.
The Foundation Models team builds large-scale generative models and reasoning frameworks for automated scientific discovery — think biology-native LLMs and diffusion models trained on multi-modal data.
The AI for Protein Engineering team develops generative and predictive models for biomolecule design, from in silico hypothesis to wet-lab validation.
The AI for Cell Biology team (newer, still being built) will work on single-cell omics, perturbation biology, and tissue modeling.
A dedicated Bioinformatics Scientist role sits in the data science team, building pipelines for automated analysis of experimental outputs.
Unlike pharma ML roles that support a defined pipeline, LSAI roles are building foundational research infrastructure — the science and the platform evolve simultaneously.
📈 Career Growth & Development
Publications
Principal spans $176K to $570K, reflecting a genuine ladder from junior researcher to tech-company-equivalent fellow. Bioinformatics scientists can grow from building analysis pipelines into ML research as the platform matures.
Growth
The company is growing rapidly with 128+ open roles as of mid-2026, meaning early hires have real opportunity to define the scope of their role.
Compensation
The closest analogy is joining a frontier AI lab (Anthropic, DeepMind) rather than a traditional pharma company — compensation, culture, and career trajectory all skew toward tech.
Overview
LILA Sciences offers unusually wide career bands for a biotech — the range between Scientist I and Distinguished/Sr. The risk is the startup nature: equity value depends on Flagship's eventual exit strategy, and the company's mandate is broad enough that priorities can shift.